Concentric Medical announced enrolment of the first patients in TREVO 2 (Thrombectomy Revascularisation of large Vessel Occlusions) at Oregon Health & Science University in Portland, Oregon, USA and at Capital Health in Trenton, New Jersey, USA. Oregon Health & Science enrolled the first patient in TREVO 2 and Capital Health was first to use the Trevo device.
TREVO 2 is a pivotal clinical trial investigating the safety and efficacy of Concentric’s Trevo Retriever for removing clot from ischaemic stroke patients. This is the first device utilising Stentriever technology, a novel method for retrieving clot from the neurovasculature.
“The continued advancement of retrieval devices is critical to our abilities to treat stroke patients,” said Erol Veznedaroglu, director of Neurosciences and Cerebrovascular and Endovascular Neurosurgery at Capital Health,Trenton, New Jersey.
“With the TREVO 2 study now underway, we are closer to bringing this important technology to acute ischaemic stroke patients in the USA,” said Helmi Lutsep, national co-principal investigator of TREVO 2 and professor of Neurology at Oregon Health & Science University, Portland, Oregon.
The TREVO 2 study will build upon Concentric’s previous clot retrieval trials, MERCI and Multi MERCI, which have provided compelling evidence of the benefits of retrieving stroke-causing clots from the blood vessels of acute ischaemic stroke patients. Leading acute ischaemic stroke centres across North America and Europe will be participating.
The Trevo Retriever was launched in Europe and other international markets in 2010 and has received positive feedback from clinicians throughout Europe and the rest of the world.
